To overcome the safety concerns, studies examining the use of a safer adenoviral WT p53 expression vector (Ad-p53) were conducted in multiple cancer subtypes and demonstrated similar effects—apoptosis induction and arrested growth in vitro and in vivo (Figure 2A), with genotoxic combination therapy resulting in a synergistic effect [113,114,115]. This evidence concerns the gene TP53 and cancer.